Benefits
Skin Comfort Self-Ratings in a Maker Survey (No Placebo)
In the maker's own 60-day survey of 50 adults aged 40 to 60 taking 300 mg a day, 76% reported less itching, 74% less facial redness and 72% less skin tightness. These are questionnaire answers from people who knew what they were taking, with no placebo group and no peer review, so they cannot show the extract caused the change.
Self-Rated Hydration and Skin Quality in the Same Survey
In the same uncontrolled survey, 74% said their skin felt more hydrated and 72% rated their overall skin quality as better. Hydration was not measured with an instrument, and no published trial has tested skin hydration or skin quality in people taking Xorialyc.
Skin Pores With a Different Olive Leaf Extract (Class Evidence)
In a placebo-controlled trial of another olive leaf extract at 250 mg a day, a 26-woman exploratory skin subgroup had fewer facial pores on skin imaging than placebo after 12 weeks, while redness, pigmentation and wrinkle depth did not differ. That product is standardised differently, so the result cannot be transferred to Xorialyc.
Antioxidant and Inflammatory Signalling in Cell Studies Only
In cultured human skin cells, luteolin dampened NF-κB activation and inflammatory messengers, and a mix of the olive compounds oleuropein, hydroxytyrosol and verbascoside reduced UVB damage markers. These are in vitro findings with pure compounds, not evidence that a capsule changes anyone's skin.
Mechanism of action
NF-κB Pathway (Cell Studies)
NF-κB is a switch that turns on inflammatory genes. In a laboratory study, luteolin blocked NF-κB activation in cultured human skin cells stimulated with TNF. That used the free flavonoid added straight to cells, whereas Xorialyc is standardised to luteolin-7-O-glucoside, and whether enough reaches the skin after swallowing a capsule is unknown.
COX-2 and Prostaglandin E2 (Maker's Unpublished Data)
The maker states that Xorialyc lowered COX-2 gene expression and prostaglandin E2 production in its own cell experiments, but these data are not published (references are available on request only). No study has measured either marker in people taking the extract.
Polyphenol Standardisation
The maker standardises Xorialyc to luteolin-7-O-glucoside and at least 20% ortho-diphenols, and also lists quercetin and protocatechuic acid. These compounds show antioxidant and anti-inflammatory activity in laboratory tests; how much of them reaches the skin after a capsule has not been studied.
Ortho-Diphenol Antioxidant Activity
Ortho-diphenols are phenols with two neighbouring hydroxyl groups, such as hydroxytyrosol, oleuropein and verbascoside; the maker specifies at least 20% of them. They are strong antioxidants in laboratory tests. In a cell study, oleuropein, hydroxytyrosol and verbascoside together reduced UVB damage markers in cultured skin cells. That was a three-compound mix applied directly to cells, not Xorialyc taken by mouth.
Clinical trials
Open, uncontrolled consumer perception survey reported by Pharmactive Biotech Products, the company that sells Xorialyc: one 300 mg capsule a day for 60 days, with questionnaires before and after. Not peer reviewed, not on PubMed and not registered on ClinicalTrials.gov. (Pharmactive Biotech Products 2025, company website)
50 healthy adults aged 40 to 60 (average 48), men and women, who reported redness, itching, tightness or irritation and were not under dermatological treatment or taking other supplements. Everyone took the product.
By self-rating, 76% reported less itching, 74% less facial redness, 74% better hydration, 72% less tightness and 72% better overall skin quality; 80% said they noticed a visible effect and 78% would recommend it. No skin measurements were taken and there was no placebo group, so expectation, season and normal ups and downs cannot be ruled out.
Class evidence: a different olive leaf extract, Bonolive (standardised to over 40% oleuropein), in a 12-week randomized, double-blind, placebo-controlled trial (NCT05744453); this secondary report covers blood markers of tissue aging, with skin as an exploratory outcome in a subgroup. Funded by Solabia BV, which employed four authors. (Lasfar et al. 2025, Frontiers in Nutrition)
65 healthy postmenopausal women aged 45 to 70 were randomized to 250 mg a day or placebo (60 analyzed); facial skin was imaged by video dermoscopy in a subgroup of 26 (10 extract, 16 placebo).
Pore number was lower than placebo at week 12 (p = 0.034). Skin redness, evenness, pigmentation and wrinkle depth did not differ from placebo, and no blood marker of tissue aging changed significantly after correction for multiple testing. A small exploratory result for another brand, not evidence for Xorialyc.